Philip Morris sells asthma inhaler company, citing unwarranted opposition' to its goals
Briefly

Health groups expressed skepticism as Philip Morris sells Vectura, claiming their transformation to a health-focused company was hindered by opposition to their tobacco roots.
Philip Morris's acquisition of Vectura for $1.2 billion was met with criticism, as the company generates significant revenue from treating smoking-related illnesses.
Read at www.npr.org
[
|
]